A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis
Authors:
- George M. LowryGLGeorge M. Lowry
- James A. NorthcuttJNJames A. Northcutt
- John HowesJHJohn Howes
- Gary D. NovackGNGary D. Novack
- Kathryn HartKHKathryn Hart
- 1 August 1998
- journal article
- clinical trial
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 102 (2) , 251-255
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- A Controlled Evaluation of the Efficacy and Safety of Loteprednol Etabonate in the Prophylactic Treatment of Seasonal Allergic ConjunctivitisAmerican Journal of Ophthalmology, 1997
- A Double-masked, Placebo-controlled Evaluation of the Efficacy and Safety of Loteprednol Etabonate in the Treatment of Giant Papillary ConjunctivitisAmerican Journal of Ophthalmology, 1997
- Adverse nondrug reactions: An update*Clinical Pharmacology & Therapeutics, 1996
- Conjunctivitis of allergic origin: Clinical presentation and differential diagnosisSurvey of Ophthalmology, 1993
- Intraocular Pressure Response to Loteprednol Etabonate in Known Steroid RespondersJournal of Ocular Pharmacology and Therapeutics, 1993
- Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyesCurrent Eye Research, 1991
- Soft drugs: Principles and methods for the design of safe drugsMedicinal Research Reviews, 1984
- Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphateCurrent Eye Research, 1984
- Adverse Nondrug ReactionsNew England Journal of Medicine, 1968